Manage Your Liver
Q:

New type of fatty liver diseases found in people who are not obese

New type of fatty liver diseases found in people who are not obese
A:

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are common liver diseases. They occur in people who drink little or no alcohol at all and are considered to be consequences of obesity. 

 

However, “not obese” does not equal “no NAFLD / NASH”, since NAFLD may not be linked with obesity in some cases. Fatty liver disease may also develop in non-obese people. The terms “lean NAFLD” and “lean NASH” are used to describe fatty liver in patients who are not overweight or obese.  Researchers also proposed the terms “nonobese fatty liver disease (NOFLD)” and “nonobese steatohepatitis (NOSH)” for this type of patients.

 

How dangerous is NOFLD & NOSH?

 

NOFLD and NOSH occur in normal weight patients, as defined by the standard parameter of body mass index (BMI). According to a study, NAFLD was reported in up to 10% of lean patients in the US. Worldwide, the prevalence of fatty liver was around 50-70% in obese persons and 15-20% in non-obese persons.

 

It is important to identify these lean fatty liver disease patients as some studies suggest that this condition is associated with a worse metabolic and liver profile than obesity-related fatty liver disease. Lean NAFLD was also more strongly linked with diabetes, hypertension, and metabolic syndrome than the common obese NAFLD we know.

 

In addition, several studies have suggested that nonobese patients with fatty liver disease have more severe inflammation, higher prevalence of severe liver fibrosis and higher mortality than obese patients.

 

Take preventive measures

The standard treatment recommendation for NAFLD patients is healthy diet and exercise. However, for NOFLD patients who are of normal weight and yet are found to have steatohepatitis, what is the most beneficial treatment?

 

Apart from the standard recommendation – exercise and diet modification, preventive strategies are also important for normal-weight patients with fatty liver. Taking preventive measures to protect liver cells can help to prevent inflammation caused by the excess amount of fat in the liver. As inflammation is the major cause of liver damage, fibrosis and cirrhosis; stopping or preventing inflammation is the key to protecting the liver and reducing the risk of severe liver diseases in the long term.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. NAFLD is one of the most common causes of liver disease in the United States. Between 30 and 40 percent of adults in the United States have NAFLD. About 3 to 12 percent of adults in the United States have NASH (a form of NAFLD in which you have inflammation and liver cell damage). [1] Recent research found that NAFLD not only increases the risk of chronic liver diseases such as NASH, l
A:
“It isn't fat but rather fibrosis that drives disease progression in people with advanced non-alcoholic steatohepatitis (NASH).”   NASH is one of the most prevalent liver diseases nowadays. NASH is related to non-alcoholic fatty liver disease (NAFLD) which is characterized by the buildup of fat in the liver. Although it is normal to have some fat in the liver, some people might develop inflammation because of this fat accumulation, this is cal
Hit Questions
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
ALT (Alanine Aminotransferase / SGPT) is an enzyme that is mainly found in liver cells. The level of ALT in our bloodstream is the primary indicator of liver health.   What does high ALT indicate? ALT enzymes are normally contained within liver cells when the liver is healthy, but when the liver cells are injured or damaged by whatever means, ALT enzymes are released into the bloodstream, causing levels to go up. Therefore, by measuring the
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us